Overview

• Shares jumped about 29% intraday to roughly $2.23 after Tilray posted fiscal Q1 2026 results ahead of expectations.
• Earnings landed at break-even per share versus a consensus loss of $0.02, with adjusted net income of $3.9 million.
• Revenue rose 5% to $209.5 million, topping the $204.55 million consensus, and adjusted EBITDA increased 9% to $10.2 million.
• Gross margin narrowed to 27% from 30%, reflecting pressure even as sales grew.
• Tilray reduced debt by $7.7 million, reported $264.8 million in cash, and cut net debt to trailing adjusted EBITDA to 0.07x, while its medical unit recently added five Germany-produced Tilray Craft flower products under the BfArM program.